CRISPR/Cas9-Mediated Gene Correction in Newborn Rabbits with Hereditary Tyrosinemia Type I

share:

Brief intro:

  • Author: Nan Li, Shixue Gou, Jiaowei Wang, Quanjun Zhang, Xingyun Huang, Jingke Xie, Li Li, Qin Jin, Zhen Ouyang, Fangbing Chen, Weikai Ge, Hui Shi, Yanhui Liang, Zhenpeng Zhuang, Xiaozhu Zhao, Meng Lian, Yinghua Ye, Longquan Quan, Han Wu, Liangxue Lai, and Kepin Wang
  • Journal: Molecular Therapy
  • Doi: https://www.doi.org/10.1016/j.ymthe.2020.11.023
  • Publication Date: 2020 Nov 20

Products/Services used in the paper

Quotation shows PackGene:AAV8 was produced and purified by PackGene Biotech. Donor template and optimal sgRNA with U6 promoter were packaged into an AAV8 with mCherry fluorescent reporter, referred to as AAV8-sgRNA4-Donor. SpCas9 with the miniCMV promoter was packaged into the other AAV8, referred to as AAV8- SpCas9. The purified AAV8 was stored in a freezer at 80C.

Research Field:liver, kidney

AAV Serotype:AAV8

Targeted organ:liver

Animal or cell line strain:New Zealand white rabbits

Request Quote

Abstract

Patients with hereditary tyrosinemia type I (HT1) present acute and irreversible liver and kidney damage during infancy. CRISPR-Cas9-mediated gene correction during infancy may provide a promising approach to treat patients with HT1. However, all previous studies were performed on adult HT1 rodent models, which cannot authentically recapitulate some symptoms of human patients. The efficacy and safety should be verified in large animals to translate precise gene therapy to clinical practice. Here, we delivered CRISPR-Cas9 and donor templates via adeno-associated virus to newborn HT1 rabbits. The lethal phenotypes could be rescued, and notably, these HT1 rabbits reached adulthood normally without 2-(2-nitro-4-trifluoromethylbenzyol)-1,3 cyclohexanedione administration and even gave birth to offspring. Adeno-associated virus (AAV)-treated HT1 rabbits displayed normal liver and kidney structures and functions. Homology-directed repair-mediated precise gene corrections and non-homologous end joining-mediated out-of-frame to in-frame corrections in the livers were observed with efficiencies of 0.90%-3.71% and 2.39%-6.35%, respectively, which appeared to be sufficient to recover liver function and decrease liver and kidney damage. This study provides useful large-animal preclinical data for rescuing hepatocyte-related monogenetic metabolic disorders with precise gene therapy.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download